Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Epidemiology

Abstract #2142: Liver enzyme elevations among cancer patients:
Results from a pooled clinical trial cohort

Sumitra Shantakumar, Sarah Landis, Jeanenne Nelson, Andy Lawton, Nittaya Suppapanya and Liaquat Ali
Sumitra Shantakumar
GlaxoSmithKline, Research Triangle Park, NC; GlaxoSmithKline, Middlesex, United Kingdom; GlaxoSmithKline, Greenford, United Kingdom; GlaxoSmithKline, Upper Providence, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah Landis
GlaxoSmithKline, Research Triangle Park, NC; GlaxoSmithKline, Middlesex, United Kingdom; GlaxoSmithKline, Greenford, United Kingdom; GlaxoSmithKline, Upper Providence, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeanenne Nelson
GlaxoSmithKline, Research Triangle Park, NC; GlaxoSmithKline, Middlesex, United Kingdom; GlaxoSmithKline, Greenford, United Kingdom; GlaxoSmithKline, Upper Providence, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andy Lawton
GlaxoSmithKline, Research Triangle Park, NC; GlaxoSmithKline, Middlesex, United Kingdom; GlaxoSmithKline, Greenford, United Kingdom; GlaxoSmithKline, Upper Providence, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nittaya Suppapanya
GlaxoSmithKline, Research Triangle Park, NC; GlaxoSmithKline, Middlesex, United Kingdom; GlaxoSmithKline, Greenford, United Kingdom; GlaxoSmithKline, Upper Providence, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Liaquat Ali
GlaxoSmithKline, Research Triangle Park, NC; GlaxoSmithKline, Middlesex, United Kingdom; GlaxoSmithKline, Greenford, United Kingdom; GlaxoSmithKline, Upper Providence, PA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published May 2009
  • Article
  • Info & Metrics
Loading
AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

Abstract

There is a paucity of epidemiologic studies investigating elevated liver function tests (LFT) among cancer patients, with the majority of data coming from case reports or clinical trial adverse event reports. Data describing LFT elevations in cancer patients would aid patient safety by providing an empirical-based context for setting study drug cessation thresholds, and informing trial exclusion criteria. We performed a retrospective pooled analysis of oncology clinical trials conducted by GlaxoSmithKline between 1985-2005 to assess the baseline prevalence and incidence of LFT elevations in cancer patients. Alanine transaminase (ALT), aspartate transaminase (AST), alkaline phosphatase (ALP), and total bilirubin (BILI) were examined as upper limits of normal using gender-specific normal range. A combination of AST or ALT \#8805;3x ULN + BILI \#8805;2x ULN + ALP <2x ULN that identifies potentially significant liver disease was also investigated. For each selected cutpoint or combination, the baseline prevalence of elevations before administration of study treatment was calculated. The cumulative incidence and person-time incidence rates (IR) of new elevations occurring during follow-up were calculated among patients who had normal liver chemistries at baseline. 95% confidence intervals (CI) were estimated. All analyses were stratified by the presence of liver metastases at baseline. We identified 3998 subjects from 31 Phase II-III oncology trials. The median age of the subjects was 61 (range, 18-90) years; 51% were male. The majority of subjects had locally advanced or metastatic disease; 29% had liver metastases at baseline. All studies included eligibility criteria related to liver function at baseline, with most requiring transaminases \#8804;2x ULN if liver metastases absent, \#8804;5x ULN if liver metastases present. The IR of new onset ALT elevations \#8805;3xULN was 5.9 per 1000 person-months (95% CI: 4.4, 7.8 per 1000 p-m) and 2.1 per 1000 person-months (95% CI: 0.8, 4.3 per 1000 p-m) for patients without and with liver metastases, respectively. No prevalent or incident cases of the combination endpoint occurred in patients with liver metastases. Among those without liver metastases, the prevalence of the combination endpoint at baseline was 0.04% (95% CI: 0%, 0.24%) and the IR of new cases during follow-up was 0.21 per 1000 person-months (95% CI: 0.01, 1.2 per 1000 p-m). Liver chemistry elevations were generally rare in this large cohort, which may be due in part to LFT-related enrolment criteria. The prevalence and incidence of liver chemistry elevations did not differ significantly by the presence of liver metastases, supporting uniform liver chemistry subject stopping criteria in oncology trials. These background rates are also useful benchmarks for assessing the clinical significance of liver enzyme elevations observed in future oncology clinical trials.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 2142.

Footnotes

  • 100th AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

  • American Association for Cancer Research
Back to top
Cancer Research: 69 (9 Supplement)
May 2009
Volume 69, Issue 9 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract #2142: Liver enzyme elevations among cancer patients: Results from a pooled clinical trial cohort
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract #2142: Liver enzyme elevations among cancer patients:
Results from a pooled clinical trial cohort
Sumitra Shantakumar, Sarah Landis, Jeanenne Nelson, Andy Lawton, Nittaya Suppapanya and Liaquat Ali
Cancer Res May 1 2009 (69) (9 Supplement) 2142;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract #2142: Liver enzyme elevations among cancer patients:
Results from a pooled clinical trial cohort
Sumitra Shantakumar, Sarah Landis, Jeanenne Nelson, Andy Lawton, Nittaya Suppapanya and Liaquat Ali
Cancer Res May 1 2009 (69) (9 Supplement) 2142;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Epidemiology

  • Abstract SY32-02: Genetic architecture of cancer and other complex diseases: Lessons learned and future directions
  • Abstract SY07-04: Diet and xenobiotic-metabolizing enzymes: Learning from controlled feeding studies in humans
  • Abstract SY08-01: Cancer in immunosuppressed populations: Epidemiologic clues to causation
Show more 3

Tobacco, Alcohol, Occupation, Medical Conditions, and Infections -- Poster Presentations - Proffered Abstracts

  • Abstract #2132: Alcohol drinking and the risk of head and neck cancer among younger, middle age and older populations
  • Abstract #2153: HPV and p53 antibodies are associated with the risk of head and neck cancer in multiple high-risk populations
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement